Introduction
Prostate cancer is the most prevalent cancer in men in Western societies (1) .
Although the majority of prostate cancers behave in an indolent manner, a small subset is highly aggressive and requires extensive treatment (2, 3) . Established prognostic parameters are limited to Gleason grade and tumor extent on biopsies, preoperative prostate-specific antigen (PSA), and clinical stage. Because these data are statistically powerful, but often insufficient for optimal individual treatment decisions, it is hoped that a better understanding of disease biology will eventually lead to the identification of clinically applicable molecular markers that enable a more reliable prediction of prostate cancer aggressiveness. Sequestosome 1 (SQSTM1 or p62) is a multifunctional adapter protein. Although the full spectrum of its functions is not known, there is growing evidence that p62 regulates apoptosis and cell survival through catabolic metabolism of molecules involved in NF-kB, mTOR, MAPK, and possibly also other signaling pathways (4) (5) (6) (7) . p62 localizes to the membranes of autophagosomes, and is itself cleared by autophagy (6, 7) . Accordingly, accumulation of p62 protein is believed to result from impaired autophagy, a condition that has been described in many tumor types, including cancers of the lung (8) , breast (9, 10) , colon (11) , mouth (12) and liver (13) .
In line with an oncogenic role, p62 accumulation has been linked to poor prognosis in some of these tumor types (8, 10, 12) .
Little is known about the role and clinical significance of p62 accumulation in prostate cancer. Two previous studies involving a total of 152 malignant and 28 benign prostate specimens reported discrepant results. One study on 73 patients described a gradual increase of the staining intensity from normal to hyperplastic, and malignant prostate tissue (14) . The other study -on 107 patients -could not confirm these data (15) . To clarify the clinical relevance of p62 expression in prostate cancer, we took advantage of our preexisting tissue microarray containing >12,000 prostate cancer specimens connected to a database with extensive clinical follow up and molecular data. Our findings demonstrate that high levels of p62 protein expression are strongly linked to an adverse phenotype and early PSA recurrence of prostate cancer, and suggest that these associations might be driven by a strong link of p62 protein accumulation to chromosomal instability. values were measured following surgery and PSA recurrence was defined as a postoperative PSA of 0.2 ng/ml and increasing at first of appearance. All prostate specimens were analyzed according to a standard procedure, including a complete embedding of the entire prostate for histological analysis (16) . The TMA manufacturing process was described earlier in detail (17) . In short, one 0.6 mm core and 5μ thick, was taken from a representative tissue block from each patient. The tissues were distributed among 27 TMA blocks, each containing 144 to 522 tumor samples. For internal controls, each TMA block also contained various control tissues, including normal prostate tissue. The molecular database attached to this TMA contained results on ERG expression in 10,678 (18) , ERG break apart FISH analysis in 7,099 (expanded from (19)) and deletion status of CHD1 (5q21) in 7, 932 (expanded from (20)) MAP3K7 (6q15) in 6,069 (expanded from (21)), PTEN (10q23) in 6,704 (expanded from (22) ) and FOXP1 (3p13) in 7,081 (expanded from (23)) cancers, and KI67 labeling Index (Ki67 LI) data in 4,426 (expanded from (24)) cancers.
Immunohistochemistry. Freshly cut TMA sections were immunostained on one day and in one experiment. Slides were deparaffinized and exposed to heatinduced antigen retrieval for 5 minutes in an autoclave at 121°C; 2 bar, in pH 9 Tris- Table 3 ), while differences in the resection margin status were not statistically significant.
Associations with other key genomic alterations of prostate cancer. Earlier studies had provided evidence for distinct molecular subgroups of prostate cancers defined by TMPRSS2:ERG fusions and several genomic deletions. Others and us had previously described a strong link between PTEN and 3p13 deletions and ERG positivity as well as between 5q21 and 6q15 deletions and ERG negativity (21-23).
To study, whether p62 expression might be particularly linked to one of these genomic deletions, p62 data were compared to preexisting findings on PTEN (10q23), FOXP1 (3p13), MAP3K7 (6q15) and CHD1 (5q21) deletions. In the analysis of all tumors, deletions of all four genes were significantly linked to high p62 expression (p<0.009 for each gene; Figure 3a) . Most of these associations were retained in the subsets of ERG negative and ERG positive cancers, although the differences failed to reach statistical significance for 3p13 in ERG-negative cancers and for 6q15 in ERG-positive cancers (Figure 3b and 3c) .
Association with tumor cell proliferation. Data on Ki67 immunohistochemistry of the cancers included in our TMA were available from a previous study (24) . Data on both Ki67 labeling index (Ki67LI) and p62 staining were available from 4,874 cancers. High levels of p62 staining were significantly linked to increased tumor cell proliferation (p<0.0001). This association was independend from the Gleason grade Table 4 ).
Associations with PSA recurrence. Follow-up data were available for 7,044 patients with interpretable p62 immunostaining on the TMA. There was a statistical significant association between high p62 expression and early PSA recurrence if all tumors were analyzed (p<0.0001; Figure 4a ), but also in the subgroups of ERG negative (p<0.0001) and ERG positive (p<0.0001) cancers (Figure 4b and 4c) .
Because of the strong association between p62 overexpression and PTEN deletions, and the important prognostic impact of PTEN deletion in prostate cancer, we performed additional analyses to estimate the combined impact of alterations of p62 and PTEN. For this analyses, we grouped tumors with moderate to strong staining (p62 high) and tumors with negative or weak staining (p62 low) and combined these groups with the PTEN status (non deleted / deleted) into four subsets of cancers : 1) cancers with low p62 expression lacking PTEN deletion, 2) cancers with high p62 
than the preoperatively determined Gleason grade (subjected to sampling errors and consequently under-grading in more than one third of cases (25)), another multivariate analysis was added. In scenario 4, the preoperative Gleason grade obtained on the original biopsy was combined with preoperative PSA, cT stage and p62 expression. If all tumors were analyzed, all scenarios suggest a strong evidence of p62 to represent an independent predictor of prognosis (Table 2 ). Separate analysis of ERG positive and ERG negative cancers revealed, that p62 expression has independent prognostic relevance in both ERG negative and ERG positive cancers in all scenarios ( Table 2 ).
Discussion
The results of this study demonstrate that cytoplasmic accumulation of p62 protein is a predictor of unfavorable tumor phenotype and early PSA recurrence in prostate cancer, which is independent of established clinico-pathological features.
Our immunohistochemical analysis revealed cytoplasmic p62 staining in 73% of our 7,822 analyzable prostate cancers. This frequency is somewhat lower than what has been observed in two earlier IHC studies reporting positive p62 staining in 91% of 45 prostate cancers employing conventional large section analysis (14) , and in 100% of 107 prostate cancers analyzed in a tissue microarray format (15) . These variances may be first of all attributable to differences in the antibodies, immunostaining protocols, and scoring criteria. That comparable high fractions of p62 positive cancers can be found with both large section and TMA approaches demonstrates that our analysis provided representative data not markedly influenced by sampling error issues that can potentially occur in studies evaluating small tissue cores measuring only 0.6 mm in diameter per patient.
The lack of unequivocal staining in normal prostate is in line with the study by Kitamura et al. (14) . These authors also failed to find any cytoplasmic positivity in 9 normal prostate glands, however, reported some faint nuclear staining which was also observed in cancer cells. Since a nuclear function of p62 is not known, it seems possible that such staining may be non-specific. The finding that cytoplasmic p62 was clearly up-regulated in cancers as compared to normal tissues, and that increasing levels of p62 paralleled cancer aggressiveness, i.e. high Gleason score, (13) . Moreover, several studies linked p62 overexpression to activation of mTOR and NF-kB signaling, two pathways that are associated to cancer development (5, 29, 30) . Cell line studies have even suggested that elevated p62 expression was associated with invasive growth properties (13, 31) .
In this study, we have not executed own functional experiments, but the large number of prostate cancers included in our project together with extensive molecular information on our tumors enabled us to obtain functional information "in silico". This approach of "functional molecular epidemiology" first demonstrated, that p62 expression -and probably also function -is completely independent of ERG activation. More than half of prostate cancers, particularly in young patients, carry gene fusions linking the androgen-regulated TMPRSS2 gene with the transcription factor ERG (18, 32) . This genomic rearrangements result in an androgen-driven overexpression of ERG in affected cells (33) . ERG activation leads to a substantial In summary, our study provides evidence that p62 is an independent major prognosticator in prostate cancer. We thus propose, that p62 expression analysis has the potential for clinical routine application -either alone, or more likely, in 13 combination with other biomarkers. Our large-scale tissue microarray approach will continue to proof highly instrumental for continuously identifying optimal prognostic biomarkers. Large scale molecular databases associated to large TMAs also enable limited "in silico" functional analyses. 
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